(In)Equity in Alzheimer’s Clinical Trials: A Long Road Ahead?
Ana Cláudia de Souza, Wyllians Vendramini Borelli, Pedro Rosa‐Neto · 2025
Read (In)Equity in Alzheimer’s Clinical Trials: A Long Road Ahead? by Ana Cláudia de Souza, Wyllians Vendramini Borelli, Pedro Rosa‐Neto (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11716948.txt.
Description
Ana Claudia de Souza, Wyllians Borelli, and Pedro Rosa-Neto present a 2025 review asking who gets left out of Alzheimer's drug trials. Dementia falls hardest on lower-income countries, yet trials of the newest antibody drugs have run mostly in a few wealthy regions and narrow populations. Fair evidence matters because drugs may act differently across groups.
The team searched trial registries and the medical literature for finished or stopped mid- and late-stage trials of anti-amyloid therapies that reported their samples. They collected sex, race, country, and schooling data for each trial's participants. The review measures how far the samples sit from the world that carries the disease. Its title's question, whether equity has a long road ahead, frames the findings.
Catalog record
| CREATOR | Ana Cláudia de Souza, Wyllians Vendramini Borelli, Pedro Rosa‐Neto |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |